Investor optimism for PTC Therapeutics is climbing ahead of confirmatory phase 3 results that could advance a U.S. filing for approval.
Investor optimism for PTC Therapeutics is climbing ahead of confirmatory phase 3 results that could advance a U.S. filing for approval.